Peter Altman
Vorstandsvorsitzender bei BIOCARDIA INC
Vermögen: 205 600 $ am 30.04.2024
Aktive Positionen von Peter Altman
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BIOCARDIA INC | Direktor/Vorstandsmitglied | 01.01.2002 | - |
Vorstandsvorsitzender | 01.01.2002 | - | |
Präsident | 01.01.2002 | - | |
Oncocyclist Biotech | Direktor/Vorstandsmitglied | 01.01.2018 | - |
BioCardia Lifesciences, Inc.
BioCardia Lifesciences, Inc. BiotechnologyHealth Technology BioCardia Lifesciences, Inc. engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in Los Angeles, CA. | Vorstandsvorsitzender | - | - |
Karriereverlauf von Peter Altman
Ehemalige bekannte Positionen von Peter Altman
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CAREDX, INC | Direktor/Vorstandsmitglied | 01.01.1999 | 01.01.2014 |
Vorstandsvorsitzender | 01.01.1999 | 01.01.2003 | |
Gründer | 01.01.1998 | 01.01.2014 | |
Lumen Therapeutics
Lumen Therapeutics Pharmaceuticals: MajorHealth Technology Lumen Therapeutics is an American biopharmaceutical company. The private company was founded by Peter Alan Altman. | Vorstandsvorsitzender | 01.01.2004 | 01.01.2005 |
Gründer | 01.01.2004 | 01.01.2005 | |
BioCardia, Inc. /Old/
BioCardia, Inc. /Old/ BiotechnologyHealth Technology BioCardia, Inc. is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The firm develops two comprehensive biotherapeutic products for cardiac arrest; CardiAMP and CardiALLO. CardiAMP is a bone marrow derived cell-based therapy for ischemic systolic heart failure patients who are not actively ischemic. CardiALLo is a allogeneic culture expanded mesenchymal bone marrow cells from a universal donor for use in multiple unrelated patients, entering Phase II development. Its other products also include Helix System and Morph Products. The company was founded in March 2002 and is headquartered in San Carlos, CA. | Direktor/Vorstandsmitglied | 01.01.2002 | - |
Vorstandsvorsitzender | 01.01.2002 | - | |
Präsident | 01.01.2002 | - | |
Ventritex, Inc.
Ventritex, Inc. Medical SpecialtiesHealth Technology Ventritex, Inc. designs, develops, manufactures and markets implantable defibrillators and related products for the treatment of ventricular tachycardia and ventricular fibrillation. | Corporate Officer/Principal | - | - |
Sinus Rhythm Technologies, Inc.
Sinus Rhythm Technologies, Inc. Medical SpecialtiesHealth Technology Sinus Rhythm Technologies, Inc. develops devices for the prevention of atrial fibrillation. It treats causes of atrial fibrillation with an implanted apparatus that creates scar tissue and blocks electrical current. The company was founded by Robert A. van Tassel and Daniel J. Sullivan is headquartered in Plymouth, MN. | Corporate Officer/Principal | - | - |
Ausbildung von Peter Altman
University of California, Berkeley | Doctorate Degree |
The University of California, San Francisco | Doctorate Degree |
Fu Foundation School of Engineering & Applied Science | Graduate Degree |
Statistik
International
Vereinigte Staaten | 12 |
Operativ
Chief Executive Officer | 5 |
Director/Board Member | 4 |
Founder | 2 |
Sektoral
Health Technology | 8 |
Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
CAREDX, INC | Health Technology |
BIOCARDIA INC | Health Technology |
Private Unternehmen | 6 |
---|---|
Ventritex, Inc.
Ventritex, Inc. Medical SpecialtiesHealth Technology Ventritex, Inc. designs, develops, manufactures and markets implantable defibrillators and related products for the treatment of ventricular tachycardia and ventricular fibrillation. | Health Technology |
Sinus Rhythm Technologies, Inc.
Sinus Rhythm Technologies, Inc. Medical SpecialtiesHealth Technology Sinus Rhythm Technologies, Inc. develops devices for the prevention of atrial fibrillation. It treats causes of atrial fibrillation with an implanted apparatus that creates scar tissue and blocks electrical current. The company was founded by Robert A. van Tassel and Daniel J. Sullivan is headquartered in Plymouth, MN. | Health Technology |
BioCardia, Inc. /Old/
BioCardia, Inc. /Old/ BiotechnologyHealth Technology BioCardia, Inc. is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The firm develops two comprehensive biotherapeutic products for cardiac arrest; CardiAMP and CardiALLO. CardiAMP is a bone marrow derived cell-based therapy for ischemic systolic heart failure patients who are not actively ischemic. CardiALLo is a allogeneic culture expanded mesenchymal bone marrow cells from a universal donor for use in multiple unrelated patients, entering Phase II development. Its other products also include Helix System and Morph Products. The company was founded in March 2002 and is headquartered in San Carlos, CA. | Health Technology |
Lumen Therapeutics
Lumen Therapeutics Pharmaceuticals: MajorHealth Technology Lumen Therapeutics is an American biopharmaceutical company. The private company was founded by Peter Alan Altman. | Health Technology |
BioCardia Lifesciences, Inc.
BioCardia Lifesciences, Inc. BiotechnologyHealth Technology BioCardia Lifesciences, Inc. engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in Los Angeles, CA. | Health Technology |
Oncocyclist Biotech |
- Börse
- Insiders
- Peter Altman
- Erfahrung